Full text is available at the source.
Abstract
Tirzepatide, a dual agonist of GIP and GLP-1 receptors, was recently approved for obesity management.
- Obesity is recognized as a significant global public health issue with increasing incidence over the past two decades.
- A comprehensive treatment approach for obesity may include behavioral therapy, medications, lifestyle changes, and bariatric surgery.
- Tirzepatide has been shown to manage blood sugar levels effectively.
- Tirzepatide may facilitate greater weight loss compared to existing GLP-1 receptor agonists.
Simplified